- Current report filing (8-K)
November 07 2011 - 4:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported): November 7,
2011
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
001-34566
|
75-2308816
|
(State or other jurisdiction of
|
(Commission File No.)
|
(IRS Employer ID No.)
|
incorporation or organization)
|
|
|
No. 14 East Hushan Road,
Tai'an City, Shandong,
271000
People's Republic of China
(Address of Principal
Executive Offices)
86-538 -620-2306
Registrant's telephone number,
including area code
____________________________________________________________
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 2.02
|
Results of Operations and Financial
Condition
|
On November 7, 2011, China Biologic Products, Inc. (the
Company) issued a press release announcing its financial results for its
fiscal quarter ended September 30, 2011. A copy of the press release, which the
Company is furnishing to the Securities and Exchange Commission, is attached as
Exhibit 99.1 and incorporated by reference herein.
The information contained in this Current Report on Form 8-K
and the exhibits attached hereto shall not be deemed to be filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange
Act), or otherwise subject to the liabilities of that section, nor shall such
information or such exhibits be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such a filing.
Item 7.01
|
Regulation FD Disclosure.
|
The information set forth in Item 2.02 above is incorporated by
reference herein.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: November 7, 2011
|
CHINA BIOLOGIC PRODUCTS, INC.
|
|
|
|
|
|
By:
/s/ Chao Ming
Zhao
|
|
Chao Ming Zhao
|
|
Chief Executive Officer
|
EXHIBIT INDEX
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024